BridgeMD
New treatment option for Circulating Tumor Cell
Official title EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
ClinicalTrials.gov ID: NCT04782557
What this study is testing
- What it's testing
- The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics. The investigators plan to perform EUS-guided portal vein and hepatic vein aspiration in GI cancers patients.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Age \>= 18 years old
- Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
- Undergoing treatment with either:
- Surgery
- Neoadjuvant chemotherapy
You likely can't join if
- Synchronous cancer of other sites
- Cardia, high lesser curve tumors, oesophagogastric junction tumors
- Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
- Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count...
- Patients unwilling to undergo follow-up assessments
- Patients with liver cirrhosis, portal hypertension and/ or gastric varices
See the full eligibility criteria
- Age \>= 18 years old
- Newly diagnosed stage II-IV distal gastric cancer, pancreatic cancer or colorectal cancer
- Undergoing treatment with either:
- Surgery
- Neoadjuvant chemotherapy
- Neoadjuvant chemoirradiation
- Palliative chemotherapy/ immunotherapy
- Synchronous cancer of other sites
- Cardia, high lesser curve tumors, oesophagogastric junction tumors
- Presence of bulky lymph nodes at lesser curve/ coeliac region precluding a clear EUS puncture site to portal vein and hepatic vein
- Patients with coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/uL
- Patients unwilling to undergo follow-up assessments
- Patients with liver cirrhosis, portal hypertension and/ or gastric varices
- Patient refusal to participate \-
The study team makes the final eligibility decision.
Where it's taking place
- Hong Kong, Hong Kong
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hong Kong, Hong Kong. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.